Stability study of recombinant 9-valent human papillomavirus vaccine based on Escherichia coli expression system

Abstract excerpt

This study reports on the long-term stability of a recombinant 9-valent HPV vaccine, addressing a gap in the literature as previous research did not extend beyond 72 months. The vaccine targets HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 and was produced using an E. coli expression system. We optimized soluble HPV L1 protein expression by truncating the N- and C-termini, resulting in HPV L1 virus-like...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cervical Cancer and HPV Research
• Share to Immunotherapy and Immune Responses
• Share to Molecular Biology Techniques and Applications